A Phase II randomized double-blind study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian cancer, however no drug has been approved for maintenance therapy in recurrent endometrial cancer by the FDA.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  endometrial cancer
• Age: - 99 Years
• Gender: All